/ARUXF
ARUXF Stock - Acrux Limited
Healthcare|BiotechnologyOTC
$0.01+0.00%
+$0.00 (+0.00%) • Dec 19
51
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.0
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.84
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $0.01
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for ARUXF
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$0.01 – $0.01
TARGET (TP)$0.01
STOP LOSS$0.01
RISK/REWARD1:NaN
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.90
52W High$0.05
52W Low$0.01
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $1.19M | $5.09M | $8.43M | $1.72M | $1.34M |
| Gross Profit | $1.19M | $1.13M | $7.87M | $-4,652,000 | $-7,591,000 |
| Gross Margin | 100.0% | 22.3% | 93.4% | -270.6% | -567.8% |
| Operating Income | $-8,972,000 | $-8,575,000 | $-5,912,000 | $-17,665,000 | $-23,626,000 |
| Net Income | $-5,945,000 | $-5,800,000 | $-764,000 | $-9,834,000 | $-12,629,000 |
| Net Margin | -499.6% | -113.9% | -9.1% | -572.1% | -944.6% |
| EPS | $-0.02 | $-0.02 | $-0.00 | $-0.03 | $-0.06 |
Company Overview
Acrux Limited, together with its subsidiaries, develops and commercializes generic and topical pharmaceuticals in Australia, Europe, the United States, and internationally. The company offers testosterone solutions, such as oral tablets, buccal tablets, subcutaneous pellets, transdermal patches, injections, and topical gels for treatment of adult males who have low or no testosterone. It also provides estradiol sprays for women under the Evamist and Lenzetto brand names for the treatment of flushes associated with menopause. The company was incorporated in 1998 and is based in West Melbourne, Australia.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
ARUXFBeat Rate
0%
Last 0 quarters
Avg Surprise
+0%
EPS vs Estimate
Beats / Misses
0/0
Last 12 quarters
Latest EPS
$-0.01
Q2 2025
EPS Surprise History
Q2 21
No data
Q4 21
No data
Q2 22
No data
Q4 22
No data
Q2 23
No data
Q2 24
No data
Q4 24
No data
Q2 25
No data
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Feb 23, 2026 | — | — | — | — |
Q2 2025 | Apr 30, 2025 | — | $-0.01 | — | — |
Q4 2024 | Oct 30, 2024 | — | $-0.01 | — | — |
Q2 2024 | Apr 30, 2024 | — | $-0.01 | — | — |
Q2 2023 | Jun 30, 2023 | — | $0.01 | — | — |
Q4 2022 | Dec 31, 2022 | — | $-0.01 | — | — |
Q2 2022 | Jun 30, 2022 | — | $-0.01 | — | — |
Q4 2021 | Dec 31, 2021 | — | $-0.01 | — | — |
Q2 2021 | Jun 30, 2021 | — | $-0.01 | — | — |
Q4 2020 | Dec 31, 2020 | — | $-0.03 | — | — |
Q2 2020 | Jun 30, 2020 | — | $-0.01 | — | — |
Q4 2019 | Dec 31, 2019 | — | $-0.03 | — | — |
Q2 2019 | Jun 30, 2019 | — | $-0.02 | — | — |
Q4 2018 | Dec 31, 2018 | — | $-0.02 | — | — |
Q2 2018 | Jun 30, 2018 | — | $-0.02 | — | — |
Q4 2017 | Dec 31, 2017 | — | $-0.04 | — | — |
Q2 2017 | Jun 30, 2017 | — | $-0.03 | — | — |
Q4 2016 | Dec 31, 2016 | — | $0.03 | — | — |
Q2 2016 | Jun 30, 2016 | — | $0.01 | — | — |
Q4 2015 | Dec 31, 2015 | — | $0.04 | — | — |
Latest News
Loading news...
Frequently Asked Questions about ARUXF
What is ARUXF's current stock price?
Acrux Limited (ARUXF) is currently trading at $0.01 per share. The stock has moved +0.00% today.
What is the analyst price target for ARUXF?
No analyst price targets are currently available for this stock.
What sector is Acrux Limited in?
Acrux Limited operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the OTC exchange.
What is ARUXF's market cap?
Acrux Limited has a market capitalization of $0.00 billion, making it a small-cap company.
Does ARUXF pay dividends?
No, Acrux Limited does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorAGNPF
Algernon Pharmaceuticals Inc.
$0.06
Mkt Cap: $0.0B
AXIM
AXIM Biotechnologies, Inc.
$0.02
Mkt Cap: $0.0B
HAVLF
HAVN Life Sciences Inc.
$0.00
Mkt Cap: $0.0B
IBOGF
Universal Ibogaine Inc.
$0.01
Mkt Cap: $0.0B
PKTX
ProtoKinetix, Incorporated
$0.01
Mkt Cap: $0.0B
RDDTF
Radient Technologies Inc.
$0.00
Mkt Cap: $0.0B
REPCF
RepliCel Life Sciences Inc.
$0.00
Mkt Cap: $0.0B
RNUGF
ReNeuron Group plc
$0.00
Mkt Cap: $0.0B
SIGY
Sigyn Therapeutics, Inc.
$1.71
Mkt Cap: $0.0B
ZLDAF
Zelira Therapeutics Limited
$0.23
Mkt Cap: $0.0B
Explore stocks similar to ARUXF for comparison